BioSpace News Archive

Drug Development

Galimedix Therapeutics Establishes Scientific Advisory Board of Renowned Retina Experts as Company Prepares to Enter Phase 2 Clinical Study with GAL-101

Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, has formed a Scientific Advisory Board (SAB).

June 10, 2024
·
3 min read
Drug Development

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

Biodexa Pharmaceuticals PLC announces that 12 month data of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis are to be presented at the prestigious biennial InSIGHT 2024 meeting in Barcelona, Spain on June 22, 2024.

June 10, 2024
·
6 min read
Business

SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company

SeaStar Medical Holding Corporation announces that three new members have joined its Board of Directors.

June 10, 2024
·
6 min read
Biotech Beach

Palisade Bio to Present at the Virtual Investor Pitch Conference - June 10, 2024

Palisade Bio, Inc. announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 12:00 PM ET.

June 10, 2024
·
1 min read
Business

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

BioSig Technologies, Inc. or, a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.

June 10, 2024
·
4 min read
Press Releases

Chemiluminescence Immunoassay Market Size, Trends, Growth, Report By 2033

June 10, 2024
·
1 min read
Drug Development

4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients

4Moving Biotech, a spin-off of 4P-Pharma committed to developing first-in-class treatments to modify the natural course of knee osteoarthritis, announces the successful achievement of the Phase 1 Lasare trial in knee osteoarthritis patients using 4P004.

June 10, 2024
·
3 min read
Drug Development

Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity

Biophytis SA, a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces that it has submitted an Investigational New Drug application with the U.S. Food and Drug Administration regarding its phase 2 OBA clinical study in obesity with BIO101.

June 10, 2024
·
5 min read
Business

Cumulus Oncology Appoints Catherine Lewis La Torre to its Board of Directors

Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to its Board of Directors.

June 10, 2024
·
3 min read
SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild to Moderate Alopecia Areata

SiSaf Ltd announced that a licensee of the ProSilic® variant of its technology has reported positive topline results from a randomised, placebo-controlled, multi-dose Phase II trial evaluating its topical treatment for mild to moderate alopecia areata, commonly known as spot baldness.

June 10, 2024
·
5 min read